Bisphosphonate treatment as a cause of jaw osteonecrosis

Oral Diseases

Volumn 13, Issue 3, 2007, Pages 346-347

  Kanat, O ^a   Ozet, A ^b   Ataergin, S ^b   Kuzhan, O ^b   Arpaci, F ^b   Ozturk, B ^b   Komurcu, S ^b   Ozturk, M ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; METRONIDAZOLE; PAMIDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACTINOMYCES; ANTIANGIOGENIC ACTIVITY; BONE INFECTION; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; DEBRIDEMENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPERBARIC OXYGEN; INFLAMMATION; JAW; LETTER; MANDIBLE; MAXILLA; MOUTH FLORA; MULTIPLE MYELOMA; NONHUMAN; PAIN; PRIORITY JOURNAL; TOOTH EXTRACTION; TREATMENT DURATION; VASCULARIZATION;

ANTI-BACTERIAL AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; JAW DISEASES; OSTEONECROSIS; TOOTH EXTRACTION;

EID: 34247353789     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2007.01320.x     Document Type: Letter

References (7)

1. Badros A, Weikel D, Salama A et al. (2006). Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 : 945 952.
2. Bamias A, Kastritis E, Bamia C et al. (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 : 8580 8587.
3. Durie BGM, Katz M, Crowley J (2005). Osteonecrosis of the jaw and bisphosphonates. N Eng J Med 353 : 99.
4. Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 : 1115 1117.
5. Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 : 1567 1575.
6. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005). Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136 : 1658 1668.
7. Migliorati CA, Siegel MA, Elting L, Schuster M (2006). Oral osteonecrosis and other long-term complications of bisphosphonate therapy. Lancet 7 : 508 514.